专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005013910A3 CHOLINERGIC MODULATION OF MICROGLIAL ACTIVATION VIA ALPHA-7 NICOTINIC RECEPTORS 审中-公开
标题翻译：通过ALPHA-7 NICOTINIC受体进行微量激活的胆固醇调节
公开(公告)号：WO2005013910A3
公开(公告)日：2005-04-28
申请号：PCT/US2004025714
申请日：2004-08-09
申请人： UNIV SOUTH FLORIDA , SHYTLE DOUGLAS , TAN JUN , SANBERG PAUL R
发明人： SHYTLE DOUGLAS , TAN JUN , SANBERG PAUL R
IPC分类号： A61K20060101 , A61K31/24 , A61K31/44
CPC分类号： A61K31/44 , A61K31/13 , A61K31/24 , A61K38/1703 , A61K45/06 , A61K2300/00
摘要： Novel therapeutic targets in the treatment of neuroimmunological and neurodegenerative disorders. Accordingly, methods of treating a neurodegenerative disorder in a patient, as well as inhibiting the release of a proinflammatory cytokine, comprising the step of contacting a target cell with a therapeutically effective amount of a cholinergic agonist, such as those chosen from the group consisting of acetycholine, nicotine, choline, galantamine, cytisine, GTS-21, or derivatives thereof, wherein the target cell is a microglia is provided.
摘要翻译：治疗神经免疫和神经退行性疾病的新型治疗靶点。因此，治疗患者神经变性疾病的方法以及抑制促炎细胞因子的释放，包括使靶细胞与治疗有效量的胆碱能激动剂例如选自以下的那些接触的步骤：乙酰胆碱，尼古丁，胆碱，加兰他敏，仙子碱，GTS-21或其衍生物，其中靶细胞是小胶质细胞。

2. 发明申请

WO2009023814A3 HUCBC TREATMENT OF AMYLOID ASSOCIATED DISEASE 审中-公开
标题翻译： HUCBC治疗AMYLOID相关疾病
公开(公告)号：WO2009023814A3
公开(公告)日：2009-05-07
申请号：PCT/US2008073265
申请日：2008-08-15
申请人： UNIV SOUTH FLORIDA , TAN JUN , SANBERG PAUL R
发明人： TAN JUN , SANBERG PAUL R
IPC分类号： A61K35/14
CPC分类号： A61K35/16 , A61K35/44 , A61K2035/122
摘要： Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer's disease, Huntington's disease, cerebral amyloid antigopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, A? phagocytic activity was increased and soluble and insoluble AB protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of AB 1-42 peptide and inhibited immune cell CD40 expression and reduced cerebral amyloid angiopathy.
摘要翻译：人类脐带血细胞（HUCBC）或HUCBC衍生的血浆的施用用于治疗淀粉样疾病，例如阿尔茨海默氏病，亨廷顿舞蹈病，脑淀粉样蛋白抗肌病和II型糖尿病。通过输注HUCBC来调节炎症反应导致淀粉样斑块和免疫相关细胞损伤的显着减少。 HUCBC输注也显着减少小鼠模型中的脑淀粉样血管病。这些作用与抑制CD40-CD40L相互作用有关，并且在免疫细胞上观察到表面表达CD-40的减少。此外，A？吞噬活性增加，可溶性和不溶性AB蛋白水平通过治疗被调节。注射HUCBC的血清也显着增加AB 1-42肽的吞噬作用并抑制免疫细胞CD40表达并减少脑淀粉样血管病。

3. 发明申请

WO2010056988A2 METHODS OF TREATING STROKE USING STEM CELL-LIKE MENSTRUAL BLOOD CELLS 审中-公开
标题翻译：使用干细胞样淋巴细胞治疗小肠的方法
公开(公告)号：WO2010056988A2
公开(公告)日：2010-05-20
申请号：PCT/US2009064379
申请日：2009-11-13
申请人： UNIV SOUTH FLORIDA , SANERON CCEL THERAPEUTICS INC , CRYO CELL INT , MEDICAL COLLEGE OF GEORGIA , SANBERG PAUL R , BORLONGAN CESARIO V , ALLICKSON JULIE
发明人： SANBERG PAUL R , BORLONGAN CESARIO V , ALLICKSON JULIE
IPC分类号： A61K35/14 , A61K38/18 , A61P7/06 , A61P25/28
CPC分类号： A61K35/14 , A61K35/30 , A61K38/185 , A61K38/1866
摘要： A cell type that is a complete match of the transplant recipient appears as an optimal scenario to open treatment options to a large patient population with minimal complications. The use of autologous bone marrow or umbilical cord blood has been proposed as a good source of stem cells for cell therapy. Menstrual blood is found to be another important source of stem cells. Assays of cultured menstrual blood reveal that they express embryonic like-stern cell phenotypic markers and neuronal phenotypic markers under appropriate conditioned media. Oxygen glucose deprivation stroke models show that OGD-exposed primary rat neurons, co- cultured with menstrual blood-derived stem cells or exposed to the media from cultured menstrual blood, exhibited significantly reduced cell death. Transplantation of menstrual blood-derived stem cells, either intracerebrally or intravenously, after experimentally induced ischemic stroke in adult rats also significantly reduced behavioral and histological impairments compared to vehicle-infused rats.
摘要翻译：与移植受体完全匹配的细胞类型似乎是最佳方案，以最小的并发症向大量患者群体开放治疗选择。已经提出使用自体骨髓或脐带血作为细胞治疗的干细胞的良好来源。月经血被认为是干细胞的另一个重要来源。培养的月经血液的测定显示，它们在合适的条件培养基下表达胚胎样细胞表型标记物和神经元表型标记物。氧葡萄糖剥夺中风模型显示，OGD暴露的原代大鼠神经元与月经血源干细胞共培养或暴露于来自培养的月经血液的培养基，显示出显着降低的细胞死亡。在实验性诱导的成年大鼠缺血性卒中后，月经血液或静脉内移植月经血源性干细胞，与载体输注大鼠相比，也显着降低了行为和组织学损伤。

4. 发明申请

WO2007081478A3 PRENATAL ADMINISTRATION OF UMBILICAL CORD STEM CELLS FOR TREATMENT OF LYSOSOMAL STORAGE DISEASES 审中-公开
标题翻译：用于治疗淋巴细胞储存疾病的脐带干细胞的初步管理
公开(公告)号：WO2007081478A3
公开(公告)日：2008-03-27
申请号：PCT/US2006047368
申请日：2006-12-12
申请人： UNIV SOUTH FLORIDA , GARBUZOVA-DAVIS SVITLANA , SANBERG PAUL R , GOGRAFE SYLVIA
发明人： GARBUZOVA-DAVIS SVITLANA , SANBERG PAUL R , GOGRAFE SYLVIA
IPC分类号： C12N5/00
CPC分类号： A61K35/44
摘要： A method of treating a fetus or embryo suspected of having a congenital condition that involves an abnormal or missing protein, the method has the steps of a. providing a plurality of human umbilical cord blood cells in a form suitable for intravenous administration; and b. administering the human umbilical cord blood cells to a mother carrying a fetus or embryo suspected of having said congenital condition. Such congenital conditions include Sanfilippo's syndrome, Hunter's syndrome, Hurler's syndrome, Tay-Sachs disease, Gaucher' s disease, von Gierke's disease, Pompes disease, Cori disease, Andersen disease, McArdle's disease, Hers disease, Tauri's disease or Type IX glycogen storage disease.
摘要翻译：一种治疗怀疑患有涉及异常或缺失蛋白质的先天性病症的胎儿或胚胎的方法，具有以下步骤：a。以适于静脉内施用的形式提供多个人脐带血细胞; 和b。将人脐带血细胞施用于携带怀疑患有先天性疾病的胎儿或胚胎的母亲。这种先天性疾病包括Sanfilippo综合征，亨特综合征，赫勒综合征，泰沙病，戈谢病，冯·吉尔克病，庞培病，康利病，安徒生病，麦卡德尔病，赫斯病，牛磺病或1型糖原贮积病。

5. 发明申请

WO2005107807A3 CEREBRAL INTRAVENTRICULAR TRANSPLANTATION AS METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS 审中-公开
标题翻译：作为治疗左心室狭窄的方法，作为宫颈静脉输送
公开(公告)号：WO2005107807A3
公开(公告)日：2006-01-19
申请号：PCT/US2005016033
申请日：2005-05-06
申请人： UNIV SOUTH FLORIDA , GARBUZOVA-DAVIS SVITLANA , BALBER ANDREW , DAVIS-SANBERG CYNDY , GENTRY TRACY , KUZMIN-NICHOLS NICOLE , SANBERG PAUL R , WILLING ALISON
发明人： GARBUZOVA-DAVIS SVITLANA , BALBER ANDREW , DAVIS-SANBERG CYNDY , GENTRY TRACY , KUZMIN-NICHOLS NICOLE , SANBERG PAUL R , WILLING ALISON
IPC分类号： A61K31/203 , A61K35/12 , A61K35/14 , A61K45/00 , A61K45/06 , C12N5/074 , C12N5/0789 , A01N1/02 , G01N33/53
CPC分类号： A61K35/28 , A61K9/0085 , A61K31/203 , A61K35/30 , A61K35/50 , A61K35/51 , A61K45/06 , A61K2035/124 , C12N5/0607 , C12N5/0647 , C12N5/0662 , C12N5/0663 , C12N5/0664 , C12N5/0665 , C12N5/0666 , C12N5/0667 , C12N5/0668 , C12N2501/13 , C12N2501/385 , C12N2506/11 , A61K2300/00
摘要： A method of treating a patient with a neurodegenerative disease, such as ALS, using progenitor cells isolated from human umbilical cord blood. Non-invasive transplantation of aldehyde dehydrogenase (ALDH + ) expressing progenitor cells provides cell replacement and protection of motor neurons.
摘要翻译：使用从人脐带血分离的祖细胞来治疗患有神经变性疾病的患者（例如ALS）的方法。表达祖细胞的醛脱氢酶（ALDH + +）表达的非侵入性移植提供了运动神经元的细胞替代和保护。

6. 发明申请

WO2006047593A3 METHOD OF POTENTIATING INFLAMMATORY AND IMMUNE MODULATION FOR CELL AND DRUG THERAPY 审中-公开
标题翻译：潜在的炎症和免疫调节细胞和药物治疗方法
公开(公告)号：WO2006047593A3
公开(公告)日：2009-05-07
申请号：PCT/US2005038565
申请日：2005-10-24
申请人： UNIV SOUTH FLORIDA , SANERON CCEL THERAPEUTICS INC , WILLING ALISON , SANBERG PAUL R , NEWMAN MARY B , SANBERG CYNDY DAVIS
发明人： WILLING ALISON , SANBERG PAUL R , NEWMAN MARY B , SANBERG CYNDY DAVIS
IPC分类号： C12N5/00 , C12N5/02 , C12N5/06 , C12N5/08
CPC分类号： G01N33/6863 , A61K35/51 , G01N2800/12 , G01N2800/324
摘要： A method for repairing animal tissue damage due to an inflammatory reaction in an animal has the steps of providing umbilical cord blood cells (UCBCs) in a pharmaceutically acceptable form; and administering a sufficient dose of UCBC at an optimal time thereby reducing the injury from the inflammatory reaction. Also provided are method of treating cerebrovascular accident, acute central nervous inflammation, multiple sclerosis, myocardial ischemia, and neonatal bronchopulmonary distress. For determining the optimal time of UCBCs administration, there is provided a kit containing antibodies for IL-8 and MCP-1.
摘要翻译：一种用于修复由于动物中的炎性反应引起的动物组织损伤的方法具有以药学上可接受的形式提供脐带血细胞（UCBC）的步骤; 并在最佳时间施用足够剂量的UCBC，从而减少炎症反应的损伤。还提供治疗脑血管意外，急性中枢神经炎，多发性硬化，心肌缺血和新生儿支气管肺窘迫的方法。为了确定UCBCs给药的最佳时间，提供了含有IL-8和MCP-1抗体的试剂盒。

7. 发明申请

WO2004022579A2 CELLULAR DELIVERY OF NATRIURETIC PEPTIDES 审中-公开
标题翻译：细胞输送蛋白质
公开(公告)号：WO2004022579A2
公开(公告)日：2004-03-18
申请号：PCT/US0328157
申请日：2003-09-08
申请人： UNIV SOUTH FLORIDA , SANCHEZ-RAMOS JUAN , SONG SHIJIE , SANBERG PAUL R , KAMATH SIDDHARTH G
发明人： SANCHEZ-RAMOS JUAN , SONG SHIJIE , SANBERG PAUL R , KAMATH SIDDHARTH G
IPC分类号： A61K35/12 , A61K48/00 , C07K20060101 , C12N5/0775 , C07K
CPC分类号： C12N5/0663 , A61K48/00 , A61K2035/124 , C12N2501/11 , C12N2501/115 , C12N2501/13 , C12N2501/385 , C12N2510/02
摘要： The present invention pertains to a method for treating deficits, such as neurological deficits, caused by focal or generalized edema associated with injury to the central nervous system, heart, liver, and kidney. The present invention further concerns a method for producing natriuretic peptides and pharmaceutical compositions comprising bone marrow stromal cells and effective amounts of retinoic acid and nerve growth factor to induce the bone marrow stromal cells to increase production of natriuretic peptides.
摘要翻译：本发明涉及一种用于治疗由与中枢神经系统，心脏，肝脏和肾脏的损伤相关的局灶性或全身性水肿引起的神经功能缺损的方法。本发明还涉及产生利钠肽和包含骨髓基质细胞和有效量的视黄酸和神经生长因子的药物组合物的方法，以诱导骨髓基质细胞增加利尿钠肽的产生。

8. 发明公开

EP0814819A4 SERTOLI CELLS AS TRANSPLANTATION FACILITATOR FOR CELL TRANSPLANTATION 失效
标题翻译：支持细胞移植SUPPORTER FOR细胞移植
公开(公告)号：EP0814819A4
公开(公告)日：2001-05-02
申请号：EP96908759
申请日：1996-03-12
申请人： UNIV SOUTH FLORIDA
发明人： SANBERG PAUL R , CAMERON DON F , BORLONGAN CESARIO V , HELLER RICHARD
IPC分类号： A61K35/12 , A61K35/30 , A61K35/48 , C12N5/071 , A61K35/00 , A01N63/00 , C12N5/06
CPC分类号： C12N5/0683 , A61K35/12 , A61K35/30 , A61K35/48 , A61K2035/122 , C12N5/0618 , C12N2502/246
摘要： A method of producing a sustained localized immunosuppressive effect in localized tissues is achieved by transplanting Sertoli cells proximate to the tissue.

9. 发明公开

EP1694826A4 COMPOSITIONS AND METHODS FOR ENHANCING NEUROPROTECTION VIA ADMINISTRATION OF STEM CELLS AND BLOOD BRAIN BARRIER PERMEABILIZERS 审中-公开
标题翻译：组合物及用于增强神经保护有关管理干细胞和permeabilizers血 - 脑屏障
公开(公告)号：EP1694826A4
公开(公告)日：2007-05-09
申请号：EP04814249
申请日：2004-12-15
申请人： UNIV SOUTH FLORIDA
发明人： BORLONGAN CESARIO V , SANBERG PAUL R
IPC分类号： A61K47/26 , A61K45/00 , A61K47/42 , C12N5/00 , C12N5/078
CPC分类号： C12N5/0634 , A61K9/0019 , A61K35/12 , A61K47/26 , A61K47/42
摘要： The present invention provides compositions and methods for enhancing the neuroprotective effect of umbilical cord blood cells. More particularly, the present invention provides methods of treating neurodegenerative disorders by administering umbilical cord blood cells and a substance capable of permeabilizing the blood brain barrier. In one embodiment, the blood brain barrier permeabilizer is mannitol. In another embodiment, the blood brain barrier permeabilizer is Cereport.

10. 发明公开

EP1575524A4 PROLIFERATED CELL LINES AND USES THEREOF 审中-公开
标题翻译：增殖细胞系和它们的用途
公开(公告)号：EP1575524A4
公开(公告)日：2008-11-05
申请号：EP03713393
申请日：2003-02-07
申请人： UNIV SOUTH FLORIDA , UNIV CHILE
发明人： CAVIEDES PABLO , CAVIEDES RAUL , FREEMAN THOMAS B , SANBERG PAUL R , CAMERON DON F
IPC分类号： C12Q1/02 , A61K35/12 , A61K35/26 , A61K45/00 , A61P1/16 , A61P3/10 , A61P5/06 , A61P9/10 , A61P17/02 , A61P19/02 , A61P21/02 , A61P25/00 , A61P25/04 , A61P25/14 , A61P25/16 , A61P25/28 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07K14/475 , C12N5/00 , C12N5/06 , A01N1/00 , A01N1/02 , A01N37/18 , A61K38/00 , A61K39/00 , C07K1/00 , C07K2/00 , C07K4/00 , C07K5/00 , C07K7/00 , C07K14/00 , C07K16/00 , C07K17/00 , G01N33/53
CPC分类号： A61K35/26 , C12N5/0018 , C12N2500/84 , C12N2502/078 , C12N2502/30 , C12N2503/02
摘要： The subject invention pertains to tumor cell lines useful for increasing the proliferation potential of any human or animal cell in culture, thereby providing immortalized or continuous cell lines and cultures. The invention also concerns proliferation factors, and compositions containing the factors, which are capable of increasing the proliferation potential of any human or other animal cell in culture. The subject invention further pertains to a method for proliferation cells in culture by contacting cells with the proliferation factors. The proliferated cells can range in plasticity and can include, for example, blast cells, fertilized ova, non-fertilized gametes, embryonic stem cells, adult stem cells, precursor or progenitor cells, and highly specialized cells. Optionally, the cells can be induced to cease proliferation. The proliferation cells of the subject invention are useful for cell therapy, cell/gene therapy, biological production of molecules, and as in vitro models for research, toxicity testing, and drug development.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式